Skip to main content
Stem Cell Research & Therapy logoLink to Stem Cell Research & Therapy
. 2024 Feb 14;15:40. doi: 10.1186/s13287-024-03663-x

Correction: Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial

Armin Attar 1,, Mohsen Farjoud Kouhanjani 2, Kamran Hessami 2, Massoud Vosough 3, Javad Kojuri 4, Mani Ramzi 5, Seyed Ali Hosseini 2, Marjan Faghih 6, Ahmad Monabati 5,7,
PMCID: PMC10865602  PMID: 38355635

Correction: Stem Cell Research & Therapy (2023) 14:264 10.1186/s13287-023-03495-1

In the original article, the authors identified that at the 3rd page of article in right column in the 12th line they had forgotten to add the name of the cell product used for the trial.

This line should be corrected as follows:

“On each day of infusion, fresh cGMP-certified clinical-grade hWJ-MSCs (Whartocell®, Cell Tech Pharmed Co. Ltd., Tehran, Iran) were transported to the catheterization laboratory in 0.9% normal saline."

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Armin Attar, Email: attar_armin@yahoo.com.

Ahmad Monabati, Email: monabati.am@gmail.com.


Articles from Stem Cell Research & Therapy are provided here courtesy of BMC

RESOURCES